Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Gotoh

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 13, 2017
Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapyMakito Miyake, Takuya Owari, Takashi Iwamoto, et al.
Japanese Journal of Clinical Oncology|December 9, 2022
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter studyMakito Miyake, Takuto Shimizu, Yuki Oda, et al.
World Journal of Surgical Oncology|February 20, 2019
The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancersMakito Miyake, Shinji Fukui, Daisuke Gotoh, et al.
Diagnostics (Basel, Switzerland)|January 24, 2020
Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the BladderYoshitaka Itami, Makito Miyake, Sayuri Ohnishi, et al.
Oncology Letters|September 21, 2020
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcomaMakito Miyake, Yuki Oda, Nobutaka Nishimura, et al.
Methods and Protocols|August 28, 2024
A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE TrialMakito Miyake, Satoshi Anai, Yusuke Iemura, et al.
Oncotarget|April 19, 2017
Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladderMakito Miyake, Shunta Hori, Yosuke Morizawa, et al.
Clinical Genitourinary Cancer|April 2, 2025
Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter StudyMakito Miyake, Nobutaka Nishimura, Yusuke Iemura, et al.
Cancer Management and Research|February 25, 2022
Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World DataMakito Miyake, Nobutaka Nishimura, Takuto Shimizu, et al.
Clinical Genitourinary Cancer|December 17, 2021
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial CarcinomaMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 13, 2017
Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapyMakito Miyake, Takuya Owari, Takashi Iwamoto, et al.
Japanese Journal of Clinical Oncology|December 9, 2022
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter studyMakito Miyake, Takuto Shimizu, Yuki Oda, et al.
World Journal of Surgical Oncology|February 20, 2019
The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancersMakito Miyake, Shinji Fukui, Daisuke Gotoh, et al.
Diagnostics (Basel, Switzerland)|January 24, 2020
Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the BladderYoshitaka Itami, Makito Miyake, Sayuri Ohnishi, et al.
Oncology Letters|September 21, 2020
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcomaMakito Miyake, Yuki Oda, Nobutaka Nishimura, et al.
Methods and Protocols|August 28, 2024
A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE TrialMakito Miyake, Satoshi Anai, Yusuke Iemura, et al.
Oncotarget|April 19, 2017
Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladderMakito Miyake, Shunta Hori, Yosuke Morizawa, et al.
Clinical Genitourinary Cancer|April 2, 2025
Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter StudyMakito Miyake, Nobutaka Nishimura, Yusuke Iemura, et al.
Cancer Management and Research|February 25, 2022
Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World DataMakito Miyake, Nobutaka Nishimura, Takuto Shimizu, et al.
Clinical Genitourinary Cancer|December 17, 2021
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial CarcinomaMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Pageof 16